DLK-dependent biphasic reactivation of herpes simplex virus latency established in the absence of antivirals

Sara Dochnal¹, Husain Merchant², Austin Schinlever^{1,3}, Aleksandra Babnis^{1,4}, Daniel P. Depledge^{2,5,6}, Angus Wilson² and Anna R. Cliffe^{1, *}.

1. Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, USA.

2. Department of Microbiology, New York University School of Medicine, New York, NY, USA.

3. Present address: Department of Microbiology, New York University School of Medicine, New York, NY, USA.

4. Present address: Technical University of Munich, School of Medicine, Institute of Virology, Munich, Germany.

5. Institute of Virology, Hannover Medical School, Hannover, Germany.

6. German Center for Infection Research (DZIF), partner site Hannover-Braunschweig, Hannover, Germany.

* Correspondence to Anna R. Cliffe, cliffe@virginia.edu

Abstract

An understanding of the molecular events that regulate entry of herpes simplex virus type 1 (HSV-1) into a latent infection of neurons and subsequent reactivation requires model systems. However, establishing a latent-like infection in cultured neurons is problematic as the release of any infectious virus can potentially superinfect the cultures. Here, we describe a new reporter virus, HSV-1 Stayput-GFP, that is defective for cell-to-cell spread. Use of this virus permits the establishment of a quiescent infection of neurons without the need for a viral DNA replication inhibitor. As such, Stayput-GFP provides a new model to study latency establishment and reactivation at the single neuron level. We demonstrate that reactivation involves an initial wave of viral gene expression consistent with the Phase I previously observed in primary neuron models where a viral DNA replication inhibitor is used during latency establishment. Phase I gene expression was dependent on the cell stress protein DLK but independent of histone demethylase activity and viral DNA replication. Progression into the later, Phase II wave of reactivation, characterized by detectable late viral protein synthesis and a requirement for histone demethylase activity, is also observed in the Stayput-GFP model system. These data demonstrate that the two waves of viral gene expression following HSV-1 reactivation are independent of secondary infection and occur when latent infections are established in the absence of a viral DNA replication inhibitor.

Importance

Herpes simplex virus-1 (HSV-1) enters a latent infection in neurons and periodically reactivates. Reactivation manifests as a variety of clinical symptoms. Studying latency and reactivation *in vitro* is invaluable to elucidating molecular mechanisms behind both processes to be targeted by therapeutics and reduce clinical consequences. Here, we describe a novel *in vitro* model system using a cell-to-cell spread defective HSV-1, known as Stayput-GFP, which allows for the study of latency and reactivation at the single neuron level. We anticipate this new model system will be an incredibly valuable tool for studying the establishment and reactivation of HSV-1 latent infection *in vitro*. Using this model, we find that initial reactivation events are dependent on cellular stress kinase DLK, but independent of histone demethylase activity and viral DNA replication. Our data therefore demonstrate the essential role of DLK in mediating a wave of lytic gene expression unique to reactivation.

Introduction

Herpes simplex virus 1 (HSV-1) is a globally prevalent pathogen with the capacity to infect neurons, including both sensory and autonomic neurons (1-4) . Following neuronal infection, HSV-1 can enter a lytic replication cycle, establish a lifelong latent infection, or potentially undergo a limited amount of lytic gene expression even prior to latency establishment (5-13). While latency is largely asymptomatic, periodic reactivation of the virus can result in manifestations including cutaneous lesions, keratitis, and encephalitis. Epidemiological studies have also linked HSV infection with an increased risk of developing late onset Alzheimer's disease (LOAD), particularly in individuals with the ApoE4 variant (14-22).

The regulated expression of viral lytic transcripts has been well characterized following lytic infection (23-25) . The HSV-1 genome enters the host cell epigenetically naked (26-28) but becomes chromatinized by histones bearing transcriptionally permissive histone modifications on the viral genome (29-38). Viral gene expression is initiated from the genome in response to viral trans-activator and tegument protein VP16. VP16 and host cell factor 1 (HCF-1) bind together and are recruited to VP16-responsive enhancer elements in the immediate early (IE) viral promoters through cellular factor POU homeodomain protein Oct-1 (39). Together, this VP16-induced complex recruits additional factors involved in transcriptional activation, including general transcription factors, ATP-dependent chromatin remodelers, and histone modifying enzymes (32, 40-44). Synthesis of the IE proteins is required for early (E) mRNA transcription. Products of the early viral genes enable viral DNA replication. Viral genome synthesis is a pre-

requisite for true-late (TL) mRNA transcription, likely due to a shift in genome accessibility and increased binding of host transcriptional machinery (45).

During HSV-1 latency, viral transcription is largely limited to a family of non-coding RNAs known as the latency-associated transcripts (LATs) (46-48). Viral lytic mRNAs are largely transcriptionally repressed and promoters assemble into silent heterochromatin marked by the tri-methylation of histone H3 lysine 27 (H3K27me3) and di/tri-methylation of histone H3 on lysine 9 (H3K9me2/3) (49-54). The initiation of viral gene expression during reactivation is induced from a heterochromatin-associated viral genome and occurs in the absence of viral activators like VP16. Latent HSV-1 therefore relies on host factors to act on the epigenetically silent viral genome and induce lytic gene expression.

The mechanisms that regulate entry into lytic gene expression to permit reactivation remain elusive. Using primary neuronal models of HSV-1 latent infection, reactivation has been found to progress in a two-step or bi-phasic manner. Phase I is characterized as a synchronous wave of lytic viral transcripts, occurring approximately 20 hours post-stimulus (25, 55-58). There is evidence that this initial induction of lytic gene expression is not dependent on the lytic trans-activator VP16, or viral protein synthesis (25, 59). Instead, cellular factors, including the stress kinases dual leucine zipper kinase (DLK) and c-Jun N terminal kinase (JNK), are required for Phase I entry (56, 58). Importantly, viral gene expression occurs despite the persistence of

heterochromatin on viral promoters. Instead, JNK-dependent histone phosphorylation of histone H3S10 results in a methyl/phospho switch, which can permit gene expression even while the repressive H3K9me3 histone modification is maintained (56). The second wave of viral lytic gene expression, Phase II, occurs approximately 48 hours post-stimulus. Phase II reactivation is characterized by the full transcriptional viral cascade, including viral DNA replication, and ultimately infectious virus production (25). In contrast to Phase I, viral protein synthesis, repressive heterochromatin removal, VP16-mediated transactivation, and viral DNA replication are required for Phase II (25, 56, 58).

In vitro systems of HSV-1 latency are required to study the mechanisms of latency establishment and reactivation that cannot be easily studied *in vivo* (60-63). *In vitro* models more readily enable the use of small molecule inhibition and knockdowns to perform functional studies, and components of the immune system can be included to understand how the host immune response impacts latency and reactivation (64, 65). However, there are complications involved in establishing latency *in vitro*. As also observed in animal models, only a sub-population of infected neurons enter a latent state whereas other neurons become lytically infected (11, 66-68). This leads to superinfection of the cultures and an inability to establish a latent infection. Therefore, many existing *in vitro* models have used viral DNA replication inhibitors, predominantly acyclovir (ACV), to establish latency *in vitro* (56, 69-74). ACV is proposed to inhibit viral DNA replication by incorporating into actively replicating viral genomes in lytic cells, although there is also evidence from ACV-resistant strains that ACV can also inhibit the

viral DNA polymerase (75-77). There are some caveats associated with ACV use. Since these inhibitors prevent complete genome synthesis, the process of DNA replication and subsequent late gene expression cannot be studied in lytic neurons during latency establishment. Moreover, whether ACV is incorporated into viral DNA and the fate of any potential ACV-incorporated genome is unknown. Therefore, new model systems are required in which latency establishment can be tracked without the need for viral DNA replication inhibitors. Such a system can also be used to determine whether the use of ACV in the cultures alters mechanisms of lytic gene expression during reactivation.

To create a novel model of latency and reactivation in which viral late protein synthesis can be tracked and that does not require viral DNA replication inhibitors, we created Stayput-GFP. In this HSV-1 reporter virus, a late viral fusion protein Us11-GFP was inserted into a previously characterized cell-to-cell spread deficient glycoprotein H deletion virus (78). The benefit of using a cell-to-cell spread defective virus is that viral DNA replication and late gene expression can still be studied during the establishment of latency, but superinfection does not occur. This is also advantageous for the study of reactivation as it ensures that only reactivation in an individual neuron is investigated without the risk of further *de novo* lytic replication by progeny virus. Using this system, we found that there is heterogeneity following neuronal infection, with a subpopulation of neurons that enter Late gene expression. This acute infection ultimately resolves over 30 days and quiescence is established without requiring viral DNA replication inhibitors. Interestingly, we find that the longer timescale required for latency establishment than

that used in previous *in vitro* model systems results in an inability to induce reactivation using only a single trigger. However, reactivation can be induced using a combination of stimuli. Importantly, using this system, we still observed criteria for Phase I gene expression, including the requirement for the cell stress-response kinase DLK, as well as viral gene expression that is independent of histone demethylase activity and viral DNA replication. Thus, Stayput-GFP provides a powerful new methodology to investigate the establishment and reactivation from latent infection at the single neuron level without the need for DNA replication inhibitors. This study also shows that Phase I gene expression occurs even if a latent infection is established in the absence of antivirals.

Results

Construction of a gH-null US11-GFP HSV-1.

To construct a recombinant HSV-1 that is deficient in cell-to-cell spread and can also be used to visualize cells containing detectable viral late protein, Us11 tagged with GFP (79) was inserted into an existing glycoprotein H (gH)-null virus, SCgHZ (78) (Fig. 1A). gH is essential for HSV-1 cell entry; it forms a heterodimer complex with gL, and together they activate the viral glycoprotein gB, which mediates fusion between the virus envelope and host cell membrane (80, 81). The GFP-tagged true-late protein is a useful indicator of both lytic infection and reactivation, and Us11-GFP wild-type virus has been used as such in several HSV-1 latency systems (55, 58, 62, 69, 82, 83). The tagged virus has previously been reported to express the full complement of HSV-1 genes, as wild-type Patton strain (79).

We first verified that the resulting virus (named Stayput-GFP) was deficient in cell-to-cell spread in non-neuronal and neuronal cells but otherwise undergoes gene expression and replication as a wild-type virus. The genome sequence and transcriptome of Stayput-GFP was validated by nanopore gDNA and direct RNA sequencing, respectively (Fig. 1B-C). As determined through plaque assay, the ability to produce infectious virus was perturbed in the gH-deletion strains but was rescued using previously constructed gH-complementing cell line, Vero-F6 (Fig. 1D, Supplemental Fig. 1). Importantly, replication in this cell line was indistinguishable from the parent SCgHZ and Us11-GFP Patton strain, which we chose for comparison as this virus has

Figure 1

FIG 1: Stayput-GFP replicates as wild-type but is unable to spread.

(A) Schematic overview of HSV-1 strain SC16, the gH-deletion mutant SCgHZ, and Stayput-GFP. The gH deletion / LacZ insertion and Us11-GFP insertion sites are shown by blue and green triangles respectively.

(B-C) Coverage plots derived from (B) nanopore gDNA sequencing and (C) nanopore direct RNA sequencing of SCgHZ and Stayput-GFP. Sequence read data were aligned against the SC16 reference genome and demonstrate a drop in coverage at the gH locus.

(D) Vero F6 cells were infected with Stayput-GFP, SCgHZ, or Us11-GFP at an MOI of 5. Infectious virus was collected over time and titrated on F6 cells (n=3 biological replicates).

(E-F) Neonatal sympathetic neurons were infected at an MOI of 0.5 PFU/cell with Stayput-GFP or Us11-GFP in the absence of DNA replication inhibitors. Us11-GFP-positive neurons were counted over time (n=3 biological replicates). Shapiro-Wilk normality test. Unpaired student's t test between Us11-GFP and Stayput-GFP.

****p<0.0001. The means and SEMs are shown.

(G) Neonatal sympathetic neurons were infected with Stayput-GFP, SCgHZ, or Us11-GFP at an MOI of 0.5 PFU/cell. Neurons were fixed at 6 hours post-infection and stained for viral protein ICP4 (red) along controls β III tubulin (green) and Hoescht stain (blue).

Supplemental Figure 1

208

209 Supplemental FIG 1: Stayput-GFP is unable to spread.

210 Plaque forming assay of Stayput-GFP on Vero (left) or gH-complementing Vero F6
 211 (right) cells 48 hours post-infection at a 10^{-7} dilution. GFP-positive area in example
 212 image reported top left of each image. Titer of viral stock reported bottom left of each
 213 image.

214

previously been used for latent infection studies in primary neurons.

To demonstrate cell-to-cell spread deficiency in neurons, we quantified GFP-positive neurons over time. Infection of murine sympathetic neurons at an MOI of 0.5 PFU/cell resulted in detectable GFP-positive neurons, which remained constant after 24 hours post-infection (Fig. 1E), while the surrounding GFP-negative neurons remained GFP-negative (Fig. 1F). This contrasts with the wild-type US11-GFP condition where the number of lytic-infected neurons increased substantially over time. Therefore, Stayput-GFP is unable to spread in neurons. At 6 hours post-infection, viral protein ICP4-positive neurons were indistinguishable between SCgHZ, Stayput-GFP, or wild-type Us11-GFP infected neurons. (Fig. 1G). Therefore, Stayput-GFP neuronal infection was equivalent to Us11-GFP upon initial infection but failed to spread within the neuronal culture.

Reactivation of Stayput-GFP in a primary neuronal model

We next wanted to confirm that Stayput-GFP undergoes reactivation in a manner comparable to the backbone SCgHZ virus, in addition to the wild-type Us11-GFP virus (Fig. 2A). Therefore, we infected mouse primary sympathetic neurons in the presence of viral DNA replication inhibitor ACV (56, 69-72). ACV prevents the production of infectious virus, and thus superinfection of the cultures. Following infection, ACV was removed, and reactivation was triggered adding a PI3-kinase inhibitor LY294002, which mimics loss of a branch of the NGF-signaling pathway in neurons (84) and has previously been found to induce reactivation (56, 65, 69, 83). Following the addition of

the reactivation stimulus, viral gene expression increased uniformly between the Stayput-GFP, SCgHZ, and wild-type Us11-GFP at 20 hours post-stimulus, the time-point of Phase I gene expression (Fig. 2C). Viral gene expression continued to increase from 20 to 48 hours for all three viruses, and GFP-positive neurons were visible for both GFP-tagged viruses by 48 hours (Fig. 2B, 2D). This indicates that even in the absence of cell-to-cell spread, reactivation progressed over a 48-hour period, initiating with viral mRNA production and later detection of viral late protein.

By 72 hours-post stimulus, GFP and viral gene transcription were significantly up-regulated in wild-type Us11-GFP in comparison to Stayput-GFP or SCgHZ, suggesting that at this time-point, the readout of reactivation for wild-type Us11-GFP is confounded by cell-to-cell spread (Fig. 2B, 2E). We are therefore unable to differentiate between genuine reactivation and downstream cell-to-cell spread using a wild-type virus. Previous attempts to reduce cell-to-cell spread include using pooled human gamma globulin or the viral DNA packaging inhibitor WAY-150138 (69, 85-87). However, using Stayput-GFP offers a built-in mechanism to prevent cell-to-cell spread during reactivation and permit quantification of the progression to reactivation at the single neuron level.

Figure 2

FIG 2: Stayput-GFP in a latency and reactivation model using ACV to promote latency establishment

(A) The latency and reactivation model scheme. Neonatal sympathetic neurons were infected with Stayput-GFP, parent virus SCgHZ, or wild-type Us11-GFP at an MOI of 7.5 PFU/cell in the presence of ACV (50 μ M). 6 days later, ACV was removed, and 2 days later, cultures were reactivated with LY294002 (20 μ M). The numbers of GFP positive neurons in a single well (containing approximately 5,000 neurons) for Stayput-GFP and wild-type Us11-GFP were counted over time (B). Viral gene expression also was quantified by RT-qPCR for immediate early (*ICP27*), early (*ICP8*), and late (*gC*) genes at 20 hours (C), 48 hours (D), and 72 hours (E) post-stimulus. Relative expression to un-reactivated samples and cellular control (mGAPDH). n=6 biological replicates from 3 litters. Normality determined by Kolmogorov-Smirnov test (B-E). Mann-Whitney (B) or Kruskal-Wallis with comparison of means (C-E). *p<0.05, **p<0.01, ***p<0.001. The means and SEMs are represented. Individual biological replicates are indicating in C-E.

Stayput-GFP can be used to create a quiescence model of neuronal infection in the absence of viral DNA replication inhibitors

As demonstrated in Figure 1, when wild-type virus is used for neuronal infection, superinfection of the cultures occurs, and a latent infection cannot be established. By infecting with Stayput-GFP, we posited that we could create a model of latency establishment without the use of DNA replication inhibitors. Following the infection of neonatal sympathetic neurons at an MOI of 7.5 PFU/cell, the number of GFP-positive neurons emerged by 1-day post-infection, increased until 3 days post-infection, and then decreased until reaching zero by 30 days post-infection (Fig. 3A). The length of time required for Us11-GFP to be lost from the cultures was surprising and may result from the previously characterized restricted cell death in neurons (88), or a gradual shut-off in protein synthesis in a sub-population of neurons that survive even late gene expression. Single-cell tracking demonstrates that most neurons that become GFP-positive also end up staining positive for cell death marker SYTOX™ Orange (Fig. 3B). All classes of lytic viral gene expression emerged by 1-day post-infection, increased by 3 days post-infection, and then decreased over the span of 40-days post-infection (Fig. 3C-E). The latency associated transcript (LAT) was detectable by 1-day post-infection and increased by 7 days post-infection (Fig. 3F). In contrast to the lytic transcripts, LAT expression was maintained over the infection scheme of 30-40 days. In comparison to lytic transcripts, LAT expression was approximately 400-fold higher from 30 days onwards. This indicated that LAT-positive neurons persisted over this period, likely reflecting entry into quiescence. In agreement with this hypothesis, at 40 days post-infection there are approximately 200 viral DNA copies per cell, demonstrating that

Figure 3

FIG 3: Stayput-GFP can be used to create a quiescence model in the absence of viral DNA replication inhibitors in neonatal sympathetic neurons

Neonatal sympathetic neurons were infected with Stayput-GFP at an MOI of 7.5 PFU/cell and the numbers of Us11-GFP positive neurons were quantified. n=9 biological replicates from 3 litters (A). Following infection, the same field of view was imaged to track GFP and SYTOX™ Orange (25 nM) over time. Lytic (C-E) and latent (F) viral transcripts (n=3) were quantified up to 40 days post-infection. Viral DNA load (n=3) (G) was also quantified up to 40 days post-infection. Individual biological replicates along with the means and SEMs are shown.

Supplemental Figure 2

Supplemental FIG 2: Stayput-GFP can be used to create a quiescence model in the absence of viral DNA replication inhibitors in adult sensory neurons

Neurons isolated from the trigeminal ganglia (TG) of female mice were infected with Stayput-GFP at an MOI of 7.5 PFU/cell. The resolution of lytic infection was monitored over time by imaging and counting GFP-positive neurons. n=12, 3 biological replicates. The mean and SEM are shown.

viral genomes persist (Fig. 3H). Together, these data show that infection of sympathetic neurons with a cell-to-cell defective virus results in a remaining population of neurons containing viral genomes and the LAT transcript. Notably, this mimics events following *in vivo* infection of mice.

We were also interested to determine whether a similar quiescent infection could be established in adult sensory neurons, as these are also a commonly used model of neuronal HSV-1 infection *in vitro* (66). Following infection with Stayput-GFP in primary trigeminal ganglia (TG) neurons, GFP also increased by 1-day post-infection and then was lost over time (Supplemental Fig. 2). Of interest, GFP was repeatedly lost within 15 days, a shorter period than that which is observed in neonatal sympathetic neurons. Therefore, the Stayput-GFP virus can be used to establish a quiescent infection of both sympathetic and sensory neurons *in vitro* without the use of viral DNA replication inhibitors.

The ability of HSV-1 to undergo reactivation decreases with length of time infected

The presence of viral genomes and LAT transcripts suggested that HSV-1 had established a quiescent infection 30 days post-infection; therefore, we hypothesized that some genomes enter latency, which is defined by an ability to reactivate in response to a stimulus. We thus attempted to reactivate cultures with LY294002 (20 μ M). However, we were unable to detect an increase in GFP-positive neurons after the addition of the trigger (Fig. 4A). We were also unable to detect a change immediate early, early, or late transcripts (data not shown). This was unexpected as LY294002 has repeatedly been

Figure 4

FIG 4: Reactivation decreases with length of time infected

Sympathetic neurons were infected with Stayput-GFP at an MOI of 7.5 PFU/cell and were treated with LY294002 when GFP-positive neurons were no longer detected (approximately 30 days post-infection). GFP-positive neurons were quantified over time; peak GFP (48 hours post-stimulus) is represented (A). Neonatal SCGs were infected at age postnatal day 8 (P8) with Stayput-GFP in the presence of ACV. ACV was removed 6 days post-infection and reactivation was triggered at the indicated times post-infection (B). Neonatal SCGs were infected as above after different lengths of time *in vitro*, representing indicated postnatal ages, and reactivated 8 days post-infection with LY294002 (C). n=12 biological replicates from 3 litters. Normality determined by Kolmogorov-Smirnov test. Unpaired student's t-test (B) or Mann-Whitney (A, C) based on normality of data. **p<0.01, ***p<0.001, ****p<0.0001. Individual biological replicates along with the means and SEMs are shown.

shown to elicit robust reactivation *in vitro* and was able to induce Stayput-GFP in a model using ACV to promote latency establishment (Fig. 2). Therefore, we sought to determine whether the inability to induce reactivation was due to the lack of ACV or the more prolonged time between initial infection and the addition of the reactivation stimulus. We infected neonatal cultures in the presence of ACV and reactivated over increasing lengths of time. ACV was removed from all cultures 6 days post-infection. We found that the number of GFP-positive neurons following addition of LY294002 decreased as the length of time infected increased (Fig. 4B). This was not likely due to a loss of viral genomes, as viral genome copy number and LAT expression remained constant over this period (Fig. 3F-G) and therefore instead reflected a more repressed viral genome unable to undergo reactivation upon PI3-kinase inhibition.

Neurons are known to undergo intrinsic maturation, even in culture (89, 90) and therefore the increased age of the neuron could have also impacted the ability of HSV-1 to undergo reactivation. Therefore, we investigated how reactivation changed with increased neuronal maturation (Fig. 4C). We infected cultured neurons with Stayput-GFP at an MOI of 7.5 at the postnatal (P) ages of P8, P16, and P24 and then reactivated 8 days later. These postnatal ages of infection were chosen to reactivate at the same ages of reactivation in Fig 4B. Importantly, we did not detect a decrease in reactivation output as the age of the neuron increased. Together, these data indicate that the decreased ability of Stayput-GFP to reactivate in a model that did not require ACV to establish quiescence was due to the longer time frame of infection and not associated with a lack of ACV in the cultures or increased age of the neuron.

Viral gene expression can be induced following long-term quiescent infection when multiple triggers are combined

We next sought to determine whether other known stimuli of HSV-1 reactivation could induce Us11-GFP expression, indicative of entry into reactivation. We attempted a number of triggers including forskolin (91-94) and heat-shock/hyperthermia (95-102), which are both known inducers of HSV-1 reactivation. Alone these stimuli did not induce Us11-GFP expression or viral lytic mRNA induction (data not shown). However, when heat-shock (43°C for 3h), in addition to forskolin (30 µM) and LY294002 (both pulsed for 20 hours) were combined, Us11-GFP positive neurons were detected at 48 hours post-stimulus, indicating progression to reactivation (Fig. 5A). Superinfection was also used as this can induce rapid and robust reactivation, likely resulting in delivery of viral tegument proteins. In comparison to superinfection, the combined heat-shock/forskolin/LY294002 trigger resulted in reduced entry into reactivation/Us11-GFP expression, indicating that only a sub-population of neurons undergo reactivation with this combined trigger, which is consistent with previous studies investigating the mechanism of HSV-1 reactivation both *in vivo* and *in vitro* (25, 70, 103, 104).

We went on to investigate whether viral mRNA expression was induced prior to the detection of Us11-GFP positive neurons. Using the triple stimulus, we detected an increase in viral lytic transcripts as early as 10 hours post-stimulus, which continued to increase, peaking at 48 hours post-stimulus (Fig. 5B-D, Supplemental Fig. 3A). Detection of immediate-early and early transcripts was slightly more robust than late transcripts,

Figure 5

FIG 5: Viral gene expression can be restarted following latency establishment

Neonatal sympathetic neurons or adult sensory neurons were infected at an MOI of 7.5 PFU/cell with Stayput-GFP in the absence of viral DNA replication inhibitors. Following the loss of GFP, signaling quiescence of the culture, wells were reactivated with a variety of triggers, including combinations of LY-294002 (20 μ M), forskolin (60 μ M), and heat shock (43°C for 3 hours), as well as a superinfection with untagged F strain at an MOI of 10 PFU/cell. GFP was quantified over time, and the peak GFP, at 48 hours post-stimulus, is depicted. N=12 biological replicates (A, E). Immediate early (B, F), early (C, G) and late (D, H) viral transcripts were investigated over time following the stimulus. Neonatal sympathetic neurons n=9 biological replicates from 3 litters. Mann-Whitney against 0 hours (A-D). Adult sensory neurons n=9 biological replicates (E) or n=3 replicates (F, G, H). Normality determined by Kolmogorov-Smirnov test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Individual biological replicates along with the means and SEMs are shown.

Supplemental Figure 3

414

415 Supplementary FIG 3: Additional viral transcripts in neonatal SCG reactivation

416 Following infection with Stayput-GFP at MOI 7.5 PFU/cell and the loss of GFP, neonatal
417 SCGs were triggered with LY294002, forskolin, and heat shock. An additional early
418 transcript (A) and late transcripts (B-E) were monitored over time. n=12, 3 biological
419 replicates, Mann-Whitney against Mock. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
420 Individual biological replicates along with the means and SEMs are shown.

although all late transcripts were significantly induced by 20 hours post-stimulus. (Fig. 5D, Supplemental Fig. 3B-E).

We also confirmed that the triple combinatorial stimulus elicits robust GFP re-emergence in adult TGs (Fig. 5E). Similar to what we observed in the sympathetic neurons, Us11-GFP positive neurons were detected by 48 hours post-stimulus. Intriguingly, superinfection only induced GFP expression to equivalent levels as the triple stimuli, which may be reflective of the repressive nature of sub-population of mature sensory neurons to lytic replication and reactivation (66, 67). Together, these data indicate that *in vitro* models of latency and reactivation can be established in sympathetic and sensory neurons in the absence of ACV and reactivation can be induced using a combination of triggers. In both models, a wave of lytic mRNA expression was detected prior to the appearance of Us11-GFP positive neurons.

Neurons infected with Stayput-GFP undergo a DLK-dependent Phase I of reactivation

Phase I reactivation has largely been investigated using *in vitro* models in which ACV has been used to promote latency establishment. In addition, Phase I has been found to occur with the single triggers of forskolin or LY294002 (25, 56, 58). The requirement for the multiple triggers for reactivation suggested that multiple cell-signaling pathways converged to have a synergistic effect and induce reactivation even in this more repressive model. Therefore, we were interested to determine whether the characteristics of Phase I reactivation occurred in the model of quiescent infection established in the absence of ACV and using the more robust trigger to induce

Figure 6

FIG 6: Reactivation is dependent on DLK

Cultures were infected with Stayput-GFP at an MOI of 7.5 PFU/cell in the absence of ACV. Following loss of GFP, cultures were reactivated with a combination of LY294002, forskolin, and heat shock in the presence of DLK inhibitor GNE-3511 (4 μ M). Immediate early (*ICP27*) and early (*ICP8/UL30*) viral genes (A-C) were investigated at 12.5 hours post stimulus, and GFP was counted over time (D). Peak GFP, consistently around 48 hours post-stimulus, is presented. n=9 biological replicates from 3 litters. Normality determined by Kolmogorov-Smirnov. Mann-Whitney test. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). The mean and SEM are shown.

reactivation. Because viral gene expression was first detected at 10-15 hours post-stimulus, potential Phase I viral transcription was investigated at 12.5 hours post-stimulus by RT-qPCR and Phase II was investigated when Us11-GFP positive neurons could be detected (48 hours post-stimulus). A characteristic of Phase I expression is the requirement of the stress kinase dual leucine zipper kinase (DLK) (56, 58). Therefore, using the DLK-specific inhibitor GNE3511 4 μ M (105), we investigated the effect of DLK on reactivation in our system. We found up-regulation of immediate early/early transcripts 12.5 hours post-stimulus was eliminated with the addition of the DLK inhibitor (Fig. 6A-C). Further, full reactivation, demonstrated by peak GFP expression at 48 hours, was also reduced to baseline levels upon the addition of the DLK inhibitor (Fig. 6D). Therefore, using our new model of HSV-1 established in the absence of ACV, our data demonstrate that the initiation of viral lytic gene expression is dependent on DLK activity.

In addition to the dependence on DLK activity, a further characteristic of Phase I gene expression is the induction of viral mRNA transcripts independently of the activity of histone de-methylase enzymes required for full reactivation. Therefore, we also triggered reactivation in the presence of de-methylase inhibitors. GSK-J4 is known to specifically inhibit the H3K27 histone demethylases UTX and JMJD3 (106) and has previously been found to inhibit HSV-1 reactivation but not Phase I gene expression (56, 58). OG-LOO2 is an LSD1 specific inhibitor. LSD1 has previously been shown to be involved in removal of H3K9me2 from HSV-1 genomes and its activity is required for full reactivation but not Phase I gene expression (42, 56, 58). However, because

histone de-methylase inhibitor independent gene expression in reactivation has only been observed in models using ACV to establish latency, we investigated their role lytic gene expression following stimulation of quiescent cultures with the triple trigger. Full reactivation was reduced in the presence of OG-LOO2 or GSK-J4 as demonstrated by GFP-positive neurons at 48 hours (Fig. 7D). However, the initial expression of lytic transcripts at 12.5 hours post-stimulation was not inhibited by either OG-LOO2 or GSK-J4 (Fig. 7A-C). Therefore, the initiation of gene expression in a manner that is independent of histone demethylase activity occurs when reactivation is induced by a triple stimulus and in a primary neuronal model in which latency was established without ACV.

During Phase I, there is no detectable replication of viral genomes even though true late gene expression occurs (56, 58). In addition, using ACV models to establish latency, late gene expression has previously been found to occur to equivalent levels when viral DNA replication is inhibited during reactivation. Although we did observe late gene expression during the initial period of lytic gene induction (12.5-20 hours), the increase was less robust than IE and E genes and appeared slightly delayed, not reaching significance for all analyzed late transcripts until 24 hours post-stimulus (Fig. 5D, Supplemental Fig. 3). Therefore, we investigated whether this late gene induction was dependent on viral DNA replication by reactivating in the presence of ACV. The addition of ACV inhibited entry in full reactivation, demonstrated by Us11-GFP positive neurons at 48 hours post-stimulus, indicating that ACV was capable of blocking robust late gene

Figure 7

Figure 7: The early phase of lytic gene expression following a reactivation stimulus is independent of demethylase activity.

Cultures were infected with Stayput-GFP at an MOI of 7.5 PFU/cell. Following loss of GFP, cultures were reactivated with a combination of LY-294002, forskolin, and heat shock in the presence of H3K27 demethylase inhibitor GSK-J4 (2 μ M) or H3K9 demethylase inhibitor OG-L002 (20 μ M). Immediate early (*ICP27*) and early (*ICP8/UL30*) viral genes (A-C) were investigated at 12.5 hours-post stimulus and GFP was counted over time (D). Peak GFP is presented. n=3 biological replicates from 3 litters. Normality determined by Kolmogorov-Smirnov. Mann-Whitney. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. The mean and SEM are shown.

expression at this late time-point (Fig. 8D). However, the addition of ACV did not inhibit the induction of lytic transcripts at 22 hours post-stimulus. Importantly, we included multiple true late genes in this analysis and all were induced to equivalent levels in the presence and absence of ACV (Fig. 8A-C). Therefore, the initial expression of late genes following a reactivation stimulus is independent of viral DNA replication. In summary, using a model system in which a quiescent infection is established without the need for ACV, all the previous characteristics of Phase I gene expression (dependence on DLK and independence of histone demethylase activity and viral DNA replication) were still observed.

Figure 8

Figure 8: Differential dependence on viral DNA replication between Phase I and II reactivation.

Cultures were infected with Stayput-GFP at an MOI of 7.5 PFU/cell in the absence of ACV. Following loss of GFP, cultures were reactivated with a combination of LY-294002, forskolin, and heat shock in the presence of ACV (50 μ M). Late (*VP16*, *gC*, *UL10*) genes (A-C) were investigated at 22 hours-post stimulus. GFP was counted over time and peak GFP is presented (D). n=12 biological replicates, normality determined by Kolmogorov-Smirnov. Mann-Whitney. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. The mean and SEM are shown.

Discussion

We envision multiple potential uses for the Stayput-GFP virus model developed here for investigating HSV-1 neuronal infection *in vitro*. The Stayput-GFP virus is advantageous in models using DNA replication inhibitors to promote latency establishment because it allows for the differentiation of *de novo* initial viral gene expression/protein synthesis events and readouts from those that are a consequence of downstream cell-to-cell spread. There have been previous attempts to control cell-to-cell spread during reactivation in this model, for example, using the DNA packaging inhibitor WAY150138 (69, 85-87). However, the use of Stayput-GFP means that synthesis of WAY150138 would not be required. In addition, even in systems where ACV is used, there can be low levels of lytic replication or spontaneous reactivation after removal of ACV from cultures. This could impact studies looking at the mechanisms of gene expression during reactivation. The use of Stayput-GFP helps limit spontaneous reactivation events by inhibiting subsequent cell-to-cell spread, while at the same time monitoring neurons that escape quiescence. Further, the GFP tag serves as an imaging indicator in real time of when lytic infection is resolved and latency is considered established. We are also able to track viral DNA replication and downstream late viral transcription and protein synthesis during the latency establishment process *in vitro*. The fate of lytic neurons, whether they undergo cell death or turn off gene expression programs and enter the latency pool, can also be investigated by tracking GFP and cell death at a single-cell level.

There are caveats and limitations to our system. Although there is some discrepancy in what defines reactivation (107), it is ultimately defined by the production of infectious virus. Due to the nature of the gH-deletion virus, *de novo* virus is by design non-infectious and we are unable to demonstrate textbook reactivation. One could theoretically resolve this issue by generating a cell line that expresses gH on its surface. However, gH activates a fusogen and is prone to cellular syncytia formation in a constitutive expression system (81). While we are unable to demonstrate infectious virus production, we do demonstrate the re-emergence of all classes of viral gene transcripts and late viral protein synthesis.

An intriguing finding in our study is that reactivation output decreases as length of infection increases. We find that, at least in the subtype of sympathetic neurons, this is independent of neuronal age or length of time in culture within the 30-day infection timeframe. The data demonstrating the persistence of viral DNA load from day 21-40 post-infection suggests this phenotype is also not due to a passive loss of viral genomes over time in culture. We also demonstrate this phenotype is independent of ACV use. A potential alternative explanation is that the viral genome becomes increasingly chromatinized over time, leading to a more repressive phenotype. In support of this hypothesis, the association of the facultative heterochromatin mark H3K27me3 with the HSV-1 genome increases dramatically between 10- and 15-days post-infection *in vivo* (50). The kinetics of H3K27me3 deposition remain to be investigated *in vitro*, but if they are mirrored this could suggest that active chromatinization and reinforcement of silencing continues even after initial shut-down of

viral gene expression. In the cellular context, H3K27me3 is linked with the recruitment of canonical Polycomb repressor complex 1 (cPRC1), which may reinforce silencing through long-range chromosomal interactions or 3D compaction (54, 108, 109). It is therefore possible that even following H3K27me3 formation on the genome, there are additional layers of protein recruitment that build up over time. In addition, it is also possible that the accumulation of viral non-coding RNAs expressed in latency could impact cellular pathways resulting in decreased signaling to the viral genome for reactivation. The use of the Stayput-GFP model system will permit these different avenues to be explored.

Our model system fits the criteria of Phase I of reactivation, which has previously been explored in *in vitro* systems using a DNA replication inhibitor. These data are interesting considering the discrepancies in conclusions drawn about reactivation between *in vitro* and *in vivo* modeling. In our model system, as in other *in vitro* systems, the progression to reactivation involves multiple waves of viral lytic gene expression. We find that viral transcripts are upregulated in a synchronous fashion, approximately 10 hours post-stimulus. There is evidence *ex vivo* for a Phase I as all classes of viral gene are expressed in a disordered, non-cascade fashion when a combination of explant and nerve-growth factor deprivation are used (110). However, in other models of reactivation *ex vivo*, there is evidence that Phase-I-like gene expression may not occur, especially from studies investigating the requirement for histone demethylase inhibitors. These latter experiments used explant (axotomy) to induce reactivation and found that the earliest induction of lytic gene expression is dependent on lysine 9

demethylase activity (41, 42). These discrepancies between *in vitro* and *ex vivo* models, or within *ex vivo* models, may result from the different trigger used to induce reactivation, although additional differences include the subtype of neuron (sensory versus sympathetic) or currently unknown effects of latency established *in vivo*. Importantly, here we have demonstrated that any potential differences between *in vivo* and *in vitro* observations on the mechanisms of reactivation do not result from the use of ACV to establish a quiescent infection. Further work using the Stayput-GFP model system will help elucidate how changes in the host immune response, neuronal subtype, and stimulus used can potentially alter the mechanisms of viral gene expression during reactivation.

Phase I, in addition to occurring synchronously and independently of histone demethylases, is also proposed to occur in the absence of viral protein synthesis. In an *in vitro* model employing ACV during latency establishment and stimulus LY294002 during reactivation, it is demonstrated that initial viral transcription occurs before the appearance of viral late protein synthesis and, specifically, independently of viral transactivator VP16 (25, 55). Therefore, cellular host factors must be responsible for instigating the initial reactivation process. Evidence from an *in vitro* model system has demonstrated these events are in fact navigated by cellular proteins JNK and DLK (56). Interestingly, host cell proteins may also be implicated in restricting the full reactivation process, including Gadd45b which appears to antagonize the HSV-1 late expression program to prevent full reactivation (55). Interestingly, Gadd45b mRNA is increased in

response to LY294002 only in infected neurons, suggesting perhaps that a viral protein may be mediating the gatekeeping from Phase I to Phase II reactivation.

In our system, Phase I gene expression was dependent on the neuronal regulator of JNK activity, DLK, highlighting the central role of DLK in HSV-1 reactivation. DLK is a cell protein implicated in neuronal stress signaling upstream of cellular protein JNK (111). It has previously been found to be essential for HSV-1 reactivation following PI3-kinase inhibition (56), as well as neuronal hyper-excitability through forskolin (58). However, it has not, until now, been shown to be central to reactivation mediated by heat shock. Although heat shock has been used as a trigger for HSV-1 reactivation (95-102), the downstream molecular events following this stimulus are not well elucidated. Heat shock has been shown to upregulate the expression of ICP0 and ICP22 in an NF- κ B site-dependent manner *in vitro* (98). Multiple studies have demonstrated that heat shock during reactivation leads to the up-regulation of heat shock proteins, although none of them relate to DLK. Following hyperthermia-induced reactivation *in vivo*, heat shock protein H2P60 and HSP40 have been demonstrated to be up-regulated (102). Components of the heat shock response pathway have also been demonstrated to be up-regulated by LY294002 treatment in an *in vitro* system (55), including HSP70. In fact, in this same system, treatment with cultures of heat shock factor 1 (HSF-1) activator compound causes robust reactivation. Outside of the virological context, heat shock protein chaperone HSP90 has been shown to bind and maintain DLK stability *in vivo* and it is specifically required for DLK function following axon injury signaling (112). It is a possibility that heat shock in our system is enhancing the function of DLK. Therefore,

multiple signals may converge on DLK, which is then able to activate JNK and protein histone phosphorylation and to promote lytic gene expression from the heterochromatin-associated viral genome for reactivation to occur. Indeed, synergy has been demonstrated to enhance DLK activity in neurons (113). This central role for DLK is especially important as it is largely a neuron-specific protein that regulates the response to multiple forms of stress (114) and is therefore a potential target for novel therapeutics that would prevent HSV-1 gene expression and ultimately reactivation.

Materials & Methods

Reagents

Compounds used in the study are as follows: Acycloguanosine, LY 294002, Forskolin, GNE-3511, GSK-J4, OG-L002. Compound concentrations were used based on previously published IC₅₀s and assessed for neuronal toxicity using the cell body and axon health and degeneration index as previously published (58).

Preparation of HSV-1 virus stocks

Stayput-GFP, as well as SCgHZ, is propagated and titrated on previously constructed gH-complementing F6 cells, which contain copies of the gH gene under the control of an HSV-1 gD promoter, as described in (78). Vero F6 cells were maintained in Dulbecco's Modified Eagle's Medium (Gibco) supplemented with 10% FetaPlex (Gemini BioProducts) and 250 µg/mL of G418/Geneticin (Gibco).

HSV-1 stocks of eGFP-Us11 Patton were grown and titrated on Vero cells obtained from the American Type Culture Collection (Manassas, VA). Cells were maintained in Dulbecco's Modified Eagle's Medium (Gibco) supplemented with 10% FetalPlex (Gemini Bio-Products) and 2 mM L-Glutamine. eGFP-Us11 Patton (HSV-1 Patton strain with eGFP reporter protein fused to true late protein Us11 (79) was kindly provided by Dr. Ian Mohr at New York University.

Construction of Stayput-GFP

Stayput-GFP was created by inserting an eUs11-GFP tag into the previously created gH-deficient HSV-1 SCgHZ virus (strain SC16) through co-transfection of SCgHZ viral DNA and pSXZY-eGFP-Us11 plasmid (79) in Vero F6 cells. Transfections were carried on in 6 well plates using 2 µg of viral DNA and 2 µg of pSXZY-eGFP-Us11 and 8ul of jetPRIME® (Polyplus). GFP-positive plaques were subjected to 4 rounds of plaque purification.

Viral genomic DNA sequencing

Genomic DNA was isolated from stocks of SCgHZ and Stayput-GFP using the Qiagen DNeasy Blood and Tissue kit. 250 ng of gDNA was used as input for the SQK-LSK109 genomic DNA by ligation protocol (Oxford Nanopore Technologies Ltd.) and resulting libraries were loaded onto individual R9.4.1 flongles for 20 hours of sequencing. Resulting raw fast5 datasets were basecalled using Guppy v4.2.2 (-f FLO-MIN106 -k SQK-RNA002) with only reads passing filter used for subsequent analyses. *De novo* assembly was performed as follows. First, HSV-1 reads were extracted from the total

pool by aligning against the HSV-1 strain SC16 reference genome (MN159383.1) using MiniMap2. HSV-1 reads shorter than 1,000 nt were subsequently filtered out prior to performing de novo assembly with Canu (115). Canu yielded a single circular contig for both SCgHZ and Stayput-GFP which was manually linearized at the canonical HSV-1 start site. Four rounds of genome polishing was performed using racon (116) before a final round of SNP calling was achieved using medaka (<https://github.com/nanoporetech/medaka>).

Direct RNA sequencing

For both SCgHZ and Stayput-GFP, NHDFs (passage 13) were infected at an MOI of 10. At 6 hours post infection, the supernatant was removed and cells washed once with PBS prior to lysing with 8 ml Trizol. Total RNA was extracted according to Trizol manufacturer's instructions and eluted in nuclease-free water. Nanopore direct RNA-Seq libraries were prepared for each sample using between ~500 ng of poly(A) RNA that was previously isolated from 30 µg of total RNA using the Dynabeads™ mRNA Purification Kit (Invitrogen, 61006). The poly(A) RNA was spiked with 0.5 µL of a synthetic Enolase 2 (ENO2) calibration RNA (Oxford Nanopore Technologies Ltd.) and direct RNA-Seq libraries prepared according to the standard SQK-RNA002 protocol (Oxford Nanopore Technologies Ltd.). Raw fast5 datasets were then basecalled using Guppy v4.2.2 (-f FLO-MIN106 -k SQK-RNA002) with only reads passing filter used for subsequent analyses. Sequence reads were aligned against the Stayput-GFP genome using MiniMap2 (Li, 2018) (-ax splice -k14 -uf --secondary=no), with subsequent parsing through SAMtools and BEDtools (117, 118). Here sequence reads were filtered to retain

only primary alignments (Alignment flag 0 (top strand) or 16 (bottom strand)). Figures associated with this study were generated using the R packages Gviz (119) and GenomicRanges (120).

Single-step growth curve

1 x 10⁵ Vero F6 cells were seeded per well in a 24-well plate. 24 hours later, when the cells had reached approximately 90% confluency, cells were infected with Stayput-GFP, SCgHZ, or wild-type Patton Us11-GFP at an MOI of 5 PFU/cell for 1 hour at 37°C with gentle rocking (60 rpm). Inoculum was then removed and replaced with 400 µL of media. At the specified time-points, 400 µL of 9% sterile milk was added to the well and the plates were frozen in the -80°C. Following three freeze thaw cycles, titrations were carried out on Vero F6 cells.

Primary neuronal cultures

Sympathetic neurons from the superior cervical ganglia (SCG) of post-natal day 0–2 (P0-P2) CD1 Mice (Charles River Laboratories) were dissected as previously described (Cliffe et al., 2015). Sensory neurons from the trigeminal ganglia (TG) or adult (P21-24) CD1 Mice (Charles River Laboratories) were dissected as previously described (121). Rodent handling and husbandry were carried out under animal protocols approved by the Animal Care and Use Committee of the University of Virginia (UVA). Ganglia were briefly kept in Leibovitz's L-15 media with 2.05 mM L-Glutamine before dissociation in Collagenase Type IV (1 mg/mL) followed by Trypsin (2.5 mg/mL) for 20 min each at 37 °C. Dissociated ganglia were triturated, and approximately 5,000 neurons per well

were plated onto rat tail collagen in a 24-well plate. Sympathetic neurons were maintained in CM1 (Neurobasal Medium supplemented with PRIME-XV IS21 Neuronal Supplement (Irvine Scientific), 50 ng/mL Mouse NGF 2.5S, 2 mM L-Glutamine, and Primocin). Aphidicolin (3.3 mg/mL) was added to the CM1 for the first 5 days post-dissection to select against proliferating cells. Sensory neurons were maintained in the same media supplemented with GDNF (50 ng/ml; Peprotech 450-44), and more Aphidicolin (6.6 mg/mL) was used for the first 5 days as more non-neuronal cells tend to be dissected with this neuron type.

Establishment and reactivation of latent HSV-1 infection in primary neurons using anti-mitotic agents

After being cultured for at least 24 hours without anti-mitotic agent aphidicolin, neonatal SCGs were infected P6-P8 with either Us11-GFP, SCgHZ, or Stayput-GFP at an MOI of 7.5 PFU/cell assuming 5,000 cells/well in DPBS +CaCl₂ +MgCl₂ supplemented with 1% Fetal Bovine Serum, 4.5 g/L glucose, and 10 mM Acyclovir (ACV) for 3 hr at 37 °C. Post-infection, inoculum was replaced with CM1 containing 50 mM ACV for 5–6 days, followed by CM1 without ACV. Reactivation was carried out in BrainPhys (Stem Cell Technologies) supplemented with 2 mM L-Glutamine, 10% Fetal Bovine Serum, Mouse NGF 2.5S (50 ng/mL) and Primocin. Reactivation was quantified by counting number of GFP-positive neurons or performing Reverse Transcription Quantitative PCR (RT-qPCR) for HSV-1 lytic transcripts.

Establishment and reactivation of latent HSV-1 infection in primary neurons without using anti-mitotic agents

After being cultured for at least 24 hours without anti-mitotic agent aphidicolin, neurons were infected P6-P8 for neonatal SCGs and P30-32 for adult TGs. The cultures were infected with Stayput-GFP at an MOI of 7.5 PFU/cell assuming 5,000 cells/well in DPBS +CaCl₂ +MgCl₂ supplemented with 1% Fetal Bovine Serum, and 4.5 g/L glucose for 3 hr at 37 °C. Post-infection, inoculum was replaced with CM1. Following the loss of GFP, reactivation was carried out in BrainPhys (Stem Cell Technologies) supplemented with 2 mM L-Glutamine, 10% Fetal Bovine Serum, Mouse NGF 2.5S (50 ng/mL) and Primocin with LY294002 20 µM and forskolin 60 µM (pulsed for 20 hours), as well as and heat shock (3 hours at 43 °C).

Immunofluorescence

Neurons were fixed for 15 min in 4% Formaldehyde and blocked in 5% Bovine Serum Albumin and 0.3% Triton X-100 and incubated overnight in primary antibody. Following primary antibody treatment, neurons were incubated for 1 hr in Alexa Fluor 488-, 555-, and 647-conjugated secondary antibodies for multi-color imaging (Invitrogen). Nuclei were stained with Hoechst 33258 (Life Technologies). Images were acquired using an sCMOS charge-coupled device camera (pco.edge) mounted on a Nikon Eclipse Ti Inverted Epifluorescent microscope using NIS-Elements software (Nikon). Images were analyzed using ImageJ.

Analysis of mRNA expression and viral genome copy number

To assess expression of HSV-1 lytic mRNA, total RNA was extracted from approximately 5,000 neurons using the Quick-RNA Miniprep Kit (Zymo Research) with an on-column DNase I digestion. mRNA was converted to cDNA using the Maxima cDNA synthesis kit (Thermo Fisher) using random hexamers for first-strand synthesis and equal amounts of RNA (20–30 ng/ reaction). To assess viral DNA load, total DNA was extracted from approximately 5,000 neurons using the Quick-DNA Miniprep Plus Kit (Zymo Research). qPCR was carried out using PowerUp™ SYBR Green Master Mix (Thermoscientific). Relative mRNA/DNA copy numbers were determined using the Comparative CT ($\Delta\Delta CT$) method normalized to mRNA levels in latently infected samples. Viral RNAs were normalized to mouse reference gene 18s ribosomal RNA. All samples were run in duplicate on an Applied Biosystems QuantStudio 6 Flex Real-Time PCR System and the mean fold change compared to the reference gene calculated. Exact copy numbers were determined by comparison to standard curves of known DNA copy number of viral genomes or plasmid containing 18S rRNA (p18S.1 tag was a gift from Vincent Mauro; Addgene plasmid # 51729 ; <http://n2t.net/addgene:51729> ; RRID:Addgene_51729, (122).

Statistical Analysis

All statistical analyses were performed using Prism V8.4. The normality test and statistical test used for each figure are denoted in the figure legends. Individual biological replicates are plotted, each corresponding to a single well of cells/neurons. All neuronal experiments were repeated from pooled neurons from at least 3 litters.

Acknowledgements

We thank Dr. Ian Mohr at New York University for the gift of the Us11-GFP virus and the pSXZY-GFP-Us11 plasmid. We thank Gary Cohen at the University of Pennsylvania for SCgHZ and Vero F6 cells. This work was supported by National Institutes of Health grants NS105630 (ARC), T32GM008136 (SD), AI130618, AI147163 and AI151358 (ACW), The Owens Family Foundation (ARC), and a German Centre for Infection Research (DZIF) Associate Professorship (DPD).

References

1. Richter ER, Dias JK, Gilbert JE, 2nd, Atherton SS. 2009. Distribution of herpes simplex virus type 1 and varicella zoster virus in ganglia of the human head and neck. *J Infect Dis* 200:1901-6.
2. Baringer JR, Pisani P. 1994. Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. *Ann Neurol* 36:823-9.
3. Baringer JR, Swoveland P. 1973. Recovery of herpes-simplex virus from human trigeminal ganglions. *N Engl J Med* 288:648-50.
4. Warren KG, Brown SM, Wroblewska Z, Gilden D, Koprowski H, Subak-Sharpe J. 1978. Isolation of latent herpes simplex virus from the superior cervical and vagus ganglions of human beings. *N Engl J Med* 298:1068-9.
5. Singh N, Tscharke DC. 2020. Herpes Simplex Virus Latency Is Noisier the Closer We Look. *J Virol* 94.
6. Bloom DC. 2016. Alpha herpesvirus Latency: A Dynamic State of Transcription and Reactivation. *Adv Virus Res* 94:53-80.
7. Speck PG, Simmons A. 1991. Divergent molecular pathways of productive and latent infection with a virulent strain of herpes simplex virus type 1. *J Virol* 65:4001-5.
8. Speck PG, Simmons A. 1992. Synchronous appearance of antigen-positive and latently infected neurons in spinal ganglia of mice infected with a virulent strain of herpes simplex virus. *J Gen Virol* 73 (Pt 5):1281-5.
9. Proenca JT, Nelson D, Nicoll MP, Connor V, Efstathiou S. 2016. Analyses of herpes simplex virus type 1 latency and reactivation at the single cell level using fluorescent reporter mice. *J Gen Virol* 97:767-777.
10. Maillat S, Naas T, Crepin S, Roque-Afonso AM, Lafay F, Efstathiou S, Labetoulle M. 2006. Herpes simplex virus type 1 latently infected neurons differentially express latency-associated and ICP0 transcripts. *J Virol* 80:9310-21.
11. Proenca JT, Coleman HM, Connor V, Winton DJ, Efstathiou S. 2008. A historical analysis of herpes simplex virus promoter activation in vivo reveals distinct populations of latently infected neurones. *J Gen Virol* 89:2965-2974.
12. Proenca JT, Coleman HM, Nicoll MP, Connor V, Preston CM, Arthur J, Efstathiou S. 2011. An investigation of herpes simplex virus promoter activity compatible with latency establishment reveals VP16-independent activation of immediate-early promoters in sensory neurones. *J Gen Virol* 92:2575-2585.
13. Chen SH, Kramer MF, Schaffer PA, Coen DM. 1997. A viral function represses accumulation of transcripts from productive-cycle genes in mouse ganglia latently infected with herpes simplex virus. *J Virol* 71:5878-84.
14. Tzeng NS, Chung CH, Lin FH, Chiang CP, Yeh CB, Huang SY, Lu RB, Chang HA, Kao YC, Yeh HW, Chiang WS, Chou YC, Tsao CH, Wu YF, Chien WC. 2018. Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan. *Neurotherapeutics* 15:417-429.

15. Letenneur L, Peres K, Fleury H, Garrigue I, Barberger-Gateau P, Helmer C, Orgogozo JM, Gauthier S, Dartigues JF. 2008. Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study. *PLoS One* 3:e3637.
16. De Chiara G, Piacentini R, Fabiani M, Mastrodonato A, Marcocci ME, Limongi D, Napoletani G, Protto V, Coluccio P, Celestino I, Li Puma DD, Grassi C, Palamara AT. 2019. Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. *PLoS Pathog* 15:e1007617.
17. Itzhaki RF. 2014. Herpes simplex virus type 1 and Alzheimer's disease: increasing evidence for a major role of the virus. *Front Aging Neurosci* 6:202.
18. Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. 1997. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. *Lancet* 349:241-4.
19. Koelle DM, Magaret A, Warren T, Schellenberg GD, Wald A. 2010. APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. *Sex Transm Infect* 86:202-6.
20. Steel AJ, Eslick GD. 2015. Herpes Viruses Increase the Risk of Alzheimer's Disease: A Meta-Analysis. *J Alzheimers Dis* 47:351-64.
21. Readhead B, Haure-Mirande JV, Funk CC, Richards MA, Shannon P, Haroutunian V, Sano M, Liang WS, Beckmann ND, Price ND, Reiman EM, Schadt EE, Ehrlich ME, Gandy S, Dudley JT. 2018. Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. *Neuron* 99:64-82 e7.
22. Lopatko Lindman K, Hemmingsson ES, Weidung B, Brannstrom J, Josefsson M, Olsson J, Elgh F, Nordstrom P, Lovheim H. 2021. Herpesvirus infections, antiviral treatment, and the risk of dementia-a registry-based cohort study in Sweden. *Alzheimers Dement (N Y)* 7:e12119.
23. Honess RW, Roizman B. 1974. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. *J Virol* 14:8-19.
24. Honess RW, Roizman B. 1975. Regulation of herpesvirus macromolecular synthesis: sequential transition of polypeptide synthesis requires functional viral polypeptides. *Proc Natl Acad Sci U S A* 72:1276-80.
25. Kim JY, Mandarino A, Chao MV, Mohr I, Wilson AC. 2012. Transient reversal of episome silencing precedes VP16-dependent transcription during reactivation of latent HSV-1 in neurons. *PLoS Pathog* 8:e1002540.
26. Lentine AF, Bachenheimer SL. 1990. Intracellular organization of herpes simplex virus type 1 DNA assayed by staphylococcal nuclease sensitivity. *Virus Res* 16:275-92.
27. Leinbach SS, Summers WC. 1980. The structure of herpes simplex virus type 1 DNA as probed by micrococcal nuclease digestion. *J Gen Virol* 51:45-59.
28. Pignatti PF, Cassai E. 1980. Analysis of herpes simplex virus nucleoprotein complexes extracted from infected cells. *J Virol* 36:816-28.
29. Conn KL, Hendzel MJ, Schang LM. 2008. Linker histones are mobilized during infection with herpes simplex virus type 1. *J Virol* 82:8629-46.
30. Conn KL, Hendzel MJ, Schang LM. 2011. Core histones H2B and H4 are mobilized during infection with herpes simplex virus 1. *J Virol* 85:13234-52.
31. Monier K, Armas JC, Etteldorf S, Ghazal P, Sullivan KF. 2000. Annexation of the interchromosomal space during viral infection. *Nat Cell Biol* 2:661-5.

32. Herrera FJ, Triezenberg SJ. 2004. VP16-dependent association of chromatin-modifying coactivators and underrepresentation of histones at immediate-early gene promoters during herpes simplex virus infection. *J Virol* 78:9689-96.
33. Kent JR, Zeng PY, Atanasiu D, Gardner J, Fraser NW, Berger SL. 2004. During lytic infection herpes simplex virus type 1 is associated with histones bearing modifications that correlate with active transcription. *J Virol* 78:10178-86.
34. Lacasse JJ, Schang LM. 2010. During lytic infections, herpes simplex virus type 1 DNA is in complexes with the properties of unstable nucleosomes. *J Virol* 84:1920-33.
35. Kutluay SB, Doroghazi J, Roemer ME, Triezenberg SJ. 2008. Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. *Virology* 373:239-47.
36. Kutluay SB, Triezenberg SJ. 2009. Regulation of histone deposition on the herpes simplex virus type 1 genome during lytic infection. *J Virol* 83:5835-45.
37. Oh J, Fraser NW. 2008. Temporal association of the herpes simplex virus genome with histone proteins during a lytic infection. *J Virol* 82:3530-7.
38. Cliffe AR, Knipe DM. 2008. Herpes simplex virus ICP0 promotes both histone removal and acetylation on viral DNA during lytic infection. *J Virol* 82:12030-8.
39. Wysocka J, Herr W. 2003. The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. *Trends Biochem Sci* 28:294-304.
40. Fan D, Wang M, Cheng A, Jia R, Yang Q, Wu Y, Zhu D, Zhao X, Chen S, Liu M, Zhang S, Ou X, Mao S, Gao Q, Sun D, Wen X, Liu Y, Yu Y, Zhang L, Tian B, Pan L, Chen X. 2020. The Role of VP16 in the Life Cycle of Alphaherpesviruses. *Front Microbiol* 11:1910.
41. Liang Y, Vogel JL, Arbuckle JH, Rai G, Jadhav A, Simeonov A, Maloney DJ, Kristie TM. 2013. Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency. *Sci Transl Med* 5:167ra5.
42. Liang Y, Vogel JL, Narayanan A, Peng H, Kristie TM. 2009. Inhibition of the histone demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency. *Nat Med* 15:1312-7.
43. Narayanan A, Ruyechan WT, Kristie TM. 2007. The coactivator host cell factor-1 mediates Set1 and MLL1 H3K4 trimethylation at herpesvirus immediate early promoters for initiation of infection. *Proc Natl Acad Sci U S A* 104:10835-40.
44. Wysocka J, Myers MP, Laherty CD, Eisenman RN, Herr W. 2003. Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1. *Genes Dev* 17:896-911.
45. Dremel SE, DeLuca NA. 2019. Herpes simplex viral nucleoprotein creates a competitive transcriptional environment facilitating robust viral transcription and host shut off. *Elife* 8.
46. Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT. 1987. RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. *Science* 235:1056-9.
47. Deatly AM, Spivack JG, Lavi E, Fraser NW. 1987. RNA from an immediate early region of the type 1 herpes simplex virus genome is present in the trigeminal ganglia of latently infected mice. *Proc Natl Acad Sci U S A* 84:3204-8.

48. Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM, Cullen BR. 2008. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. *Nature* 454:780-3.
49. Wang QY, Zhou C, Johnson KE, Colgrove RC, Coen DM, Knipe DM. 2005. Herpesviral latency-associated transcript gene promotes assembly of heterochromatin on viral lytic-gene promoters in latent infection. *Proc Natl Acad Sci U S A* 102:16055-9.
50. Cliffe AR, Coen DM, Knipe DM. 2013. Kinetics of facultative heterochromatin and polycomb group protein association with the herpes simplex viral genome during establishment of latent infection. *mBio* 4.
51. Cliffe AR, Garber DA, Knipe DM. 2009. Transcription of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promoters. *J Virol* 83:8182-90.
52. Knipe DM, Cliffe A. 2008. Chromatin control of herpes simplex virus lytic and latent infection. *Nat Rev Microbiol* 6:211-21.
53. Kwiatkowski DL, Thompson HW, Bloom DC. 2009. The polycomb group protein Bmi1 binds to the herpes simplex virus 1 latent genome and maintains repressive histone marks during latency. *J Virol* 83:8173-81.
54. Dochnal SA, Francois AK, Cliffe AR. 2021. De Novo Polycomb Recruitment: Lessons from Latent Herpesviruses. *Viruses* 13.
55. Hu HL, Srinivas KP, Wang S, Chao MV, Lionnet T, Mohr I, Wilson AC, Depledge DP, Huang TT. 2022. Single-cell transcriptomics identifies Gadd45b as a regulator of herpesvirus-reactivating neurons. *EMBO Rep* 23:e53543.
56. Cliffe AR, Arbuckle JH, Vogel JL, Geden MJ, Rothbart SB, Cusack CL, Strahl BD, Kristie TM, Deshmukh M. 2015. Neuronal Stress Pathway Mediating a Histone Methyl/Phospho Switch Is Required for Herpes Simplex Virus Reactivation. *Cell Host Microbe* 18:649-58.
57. Cliffe AR, Wilson AC. 2017. Restarting Lytic Gene Transcription at the Onset of Herpes Simplex Virus Reactivation. *J Virol* 91.
58. Cuddy SR, Schinlever AR, Dochnal S, Seegren PV, Suzich J, Kundu P, Downs TK, Farah M, Desai BN, Boutell C, Cliffe AR. 2020. Neuronal hyperexcitability is a DLK-dependent trigger of herpes simplex virus reactivation that can be induced by IL-1. *Elife* 9.
59. Steiner I, Spivack JG, Deshmane SL, Ace CI, Preston CM, Fraser NW. 1990. A herpes simplex virus type 1 mutant containing a nontransducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia. *J Virol* 64:1630-8.
60. Wilson AC, Mohr I. 2012. A cultured affair: HSV latency and reactivation in neurons. *Trends Microbiol* 20:604-11.
61. Lachmann R. 2003. Herpes simplex virus latency. *Expert Rev Mol Med* 5:1-14.
62. Pourchet A, Modrek AS, Placantonakis DG, Mohr I, Wilson AC. 2017. Modeling HSV-1 Latency in Human Embryonic Stem Cell-Derived Neurons. *Pathogens* 6.
63. Suzich JB, Cliffe AR. 2018. Strength in diversity: Understanding the pathways to herpes simplex virus reactivation. *Virology* 522:81-91.
64. Suzich JB, Cuddy SR, Baidas H, Dochnal S, Ke E, Schinlever AR, Babnis A, Boutell C, Cliffe AR. 2021. PML-NB-dependent type I interferon memory results in a restricted form of HSV latency. *EMBO Rep* 22:e52547.

982 65. Linderman JA, Kobayashi M, Rayannavar V, Fak JJ, Darnell RB, Chao MV, Wilson AC, Mohr
983 I. 2017. Immune Escape via a Transient Gene Expression Program Enables Productive
984 Replication of a Latent Pathogen. *Cell Rep* 18:1312-1323.

985 66. Bertke AS, Swanson SM, Chen J, Imai Y, Kinchington PR, Margolis TP. 2011. A5-positive
986 primary sensory neurons are nonpermissive for productive infection with herpes simplex
987 virus 1 in vitro. *J Virol* 85:6669-77.

988 67. Cabrera JR, Charron AJ, Leib DA. 2018. Neuronal Subtype Determines Herpes Simplex Virus
989 1 Latency-Associated-Transcript Promoter Activity during Latency. *J Virol* 92.

990 68. Arthur JL, Scarpini CG, Connor V, Lachmann RH, Tolkovsky AM, Efsthathiou S. 2001. Herpes
991 simplex virus type 1 promoter activity during latency establishment, maintenance, and
992 reactivation in primary dorsal root neurons in vitro. *J Virol* 75:3885-95.

993 69. Camarena V, Kobayashi M, Kim JY, Roehm P, Perez R, Gardner J, Wilson AC, Mohr I, Chao
994 MV. 2010. Nature and duration of growth factor signaling through receptor tyrosine kinases
995 regulates HSV-1 latency in neurons. *Cell Host Microbe* 8:320-30.

996 70. Yanez AA, Harrell T, Sriranganathan HJ, Ives AM, Bertke AS. 2017. Neurotrophic Factors
997 NGF, GDNF and NTN Selectively Modulate HSV1 and HSV2 Lytic Infection and Reactivation
998 in Primary Adult Sensory and Autonomic Neurons. *Pathogens* 6.

999 71. Wilcox CL, Johnson EM, Jr. 1988. Characterization of nerve growth factor-dependent herpes
1000 simplex virus latency in neurons in vitro. *J Virol* 62:393-9.

1001 72. Wilcox CL, Smith RL, Freed CR, Johnson EM, Jr. 1990. Nerve growth factor-dependence of
1002 herpes simplex virus latency in peripheral sympathetic and sensory neurons in vitro. *J*
1003 *Neurosci* 10:1268-75.

1004 73. Thellman NM, Botting C, Madaj Z, Triezenberg SJ. 2017. An Immortalized Human Dorsal
1005 Root Ganglion Cell Line Provides a Novel Context To Study Herpes Simplex Virus 1 Latency
1006 and Reactivation. *J Virol* 91.

1007 74. Edwards TG, Bloom DC. 2019. Lund Human Mesencephalic (LUHMES) Neuronal Cell Line
1008 Supports Herpes Simplex Virus 1 Latency In Vitro. *J Virol* 93.

1009 75. De Clercq E. 2008. The discovery of antiviral agents: ten different compounds, ten different
1010 stories. *Med Res Rev* 28:929-53.

1011 76. De Clercq E, Holy A. 2005. Acyclic nucleoside phosphonates: a key class of antiviral drugs.
1012 *Nat Rev Drug Discov* 4:928-40.

1013 77. Morfin F, Thouvenot D. 2003. Herpes simplex virus resistance to antiviral drugs. *J Clin Virol*
1014 26:29-37.

1015 78. Forrester A, Farrell H, Wilkinson G, Kaye J, Davis-Poynter N, Minson T. 1992. Construction
1016 and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding
1017 sequences deleted. *J Virol* 66:341-8.

1018 79. Benboudjema L, Mulvey M, Gao Y, Pimplikar SW, Mohr I. 2003. Association of the herpes
1019 simplex virus type 1 Us11 gene product with the cellular kinesin light-chain-related protein
1020 PAT1 results in the redistribution of both polypeptides. *J Virol* 77:9192-203.

1021 80. Hilterbrand AT, Heldwein EE. 2019. Go go gadget glycoprotein!: HSV-1 draws on its sizeable
1022 glycoprotein tool kit to customize its diverse entry routes. *PLoS Pathog* 15:e1007660.

1023 81. Turner A, Bruun B, Minson T, Browne H. 1998. Glycoproteins gB, gD, and gHgL of herpes
1024 simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a Cos cell
1025 transfection system. *J Virol* 72:873-5.

- 1026 82. Hu HL, Shiflett LA, Kobayashi M, Chao MV, Wilson AC, Mohr I, Huang TT. 2019.
1027 TOP2beta-Dependent Nuclear DNA Damage Shapes Extracellular Growth Factor Responses
1028 via Dynamic AKT Phosphorylation to Control Virus Latency. *Mol Cell* 74:466-480 e4.
- 1029 83. Kobayashi M, Kim JY, Camarena V, Roehm PC, Chao MV, Wilson AC, Mohr I. 2012. A
1030 primary neuron culture system for the study of herpes simplex virus latency and reactivation.
1031 *J Vis Exp* doi:10.3791/3823.
- 1032 84. Chao MV. 2003. Neurotrophins and their receptors: a convergence point for many signalling
1033 pathways. *Nat Rev Neurosci* 4:299-309.
- 1034 85. van Zeijl M, Fairhurst J, Jones TR, Vernon SK, Morin J, LaRocque J, Feld B, O'Hara B, Bloom
1035 JD, Johann SV. 2000. Novel class of thiourea compounds that inhibit herpes simplex virus
1036 type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene. *J Virol* 74:9054-61.
- 1037 86. Newcomb WW, Brown JC. 2002. Inhibition of herpes simplex virus replication by WAY-
1038 150138: assembly of capsids depleted of the portal and terminase proteins involved in DNA
1039 encapsidation. *J Virol* 76:10084-8.
- 1040 87. Pesola JM, Zhu J, Knipe DM, Coen DM. 2005. Herpes simplex virus 1 immediate-early and
1041 early gene expression during reactivation from latency under conditions that prevent
1042 infectious virus production. *J Virol* 79:14516-25.
- 1043 88. Hollville E, Romero SE, Deshmukh M. 2019. Apoptotic cell death regulation in neurons.
1044 *FEBS J* 286:3276-3298.
- 1045 89. Annis RP, Swahari V, Nakamura A, Xie AX, Hammond SM, Deshmukh M. 2016. Mature
1046 neurons dynamically restrict apoptosis via redundant premitochondrial brakes. *FEBS J*
1047 283:4569-4582.
- 1048 90. Kole AJ, Swahari V, Hammond SM, Deshmukh M. 2011. miR-29b is activated during
1049 neuronal maturation and targets BH3-only genes to restrict apoptosis. *Genes Dev* 25:125-30.
- 1050 91. Smith RL, Pizer LI, Johnson EM, Jr., Wilcox CL. 1992. Activation of second-messenger
1051 pathways reactivates latent herpes simplex virus in neuronal cultures. *Virology* 188:311-8.
- 1052 92. Colgin MA, Smith RL, Wilcox CL. 2001. Inducible cyclic AMP early repressor produces
1053 reactivation of latent herpes simplex virus type 1 in neurons in vitro. *J Virol* 75:2912-20.
- 1054 93. De Regge N, Van Opdenbosch N, Nauwynck HJ, Efstathiou S, Favoreel HW. 2010. Interferon
1055 alpha induces establishment of alphaherpesvirus latency in sensory neurons in vitro. *PLoS*
1056 *One* 5.
- 1057 94. Danaher RJ, Jacob RJ, Miller CS. 2003. Herpesvirus quiescence in neuronal cells. V: forskolin-
1058 responsiveness of the herpes simplex virus type 1 alpha0 promoter and contribution of the
1059 putative cAMP response element. *J Neurovirol* 9:489-97.
- 1060 95. Moriya A, Yoshiki A, Kita M, Fushiki S, Imanishi J. 1994. Heat shock-induced reactivation of
1061 herpes simplex virus type 1 in latently infected mouse trigeminal ganglion cells in dissociated
1062 culture. *Arch Virol* 135:419-25.
- 1063 96. Halford WP, Gebhardt BM, Carr DJ. 1996. Mechanisms of herpes simplex virus type 1
1064 reactivation. *J Virol* 70:5051-60.
- 1065 97. Halford WP, Schaffer PA. 2001. ICP0 is required for efficient reactivation of herpes simplex
1066 virus type 1 from neuronal latency. *J Virol* 75:3240-9.
- 1067 98. Kushnir AS, Davido DJ, Schaffer PA. 2010. Role of nuclear factor Y in stress-induced
1068 activation of the herpes simplex virus type 1 ICP0 promoter. *J Virol* 84:188-200.

99. Sawtell NM, Thompson RL. 1992. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. *J Virol* 66:2150-6.
100. Perng GC, Osorio N, Jiang X, Geertsema R, Hsiang C, Brown D, BenMohamed L, Wechsler SL. 2016. Large Amounts of Reactivated Virus in Tears Precedes Recurrent Herpes Stromal Keratitis in Stressed Rabbits Latently Infected with Herpes Simplex Virus. *Curr Eye Res* 41:284-91.
101. Shimomura Y, Higaki S, Watanabe K. 2010. Suppression of herpes simplex virus 1 reactivation in a mouse eye model by cyclooxygenase inhibitor, heat shock protein inhibitor, and adenosine monophosphate. *Jpn J Ophthalmol* 54:187-90.
102. Hill JM, Lukiw WJ, Gebhardt BM, Higaki S, Loutsch JM, Myles ME, Thompson HW, Kwon BS, Bazan NG, Kaufman HE. 2001. Gene expression analyzed by microarrays in HSV-1 latent mouse trigeminal ganglion following heat stress. *Virus Genes* 23:273-80.
103. Sawtell NM, Thompson RL. 2004. Comparison of herpes simplex virus reactivation in ganglia in vivo and in explants demonstrates quantitative and qualitative differences. *J Virol* 78:7784-94.
104. Thompson RL, Preston CM, Sawtell NM. 2009. De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. *PLoS Pathog* 5:e1000352.
105. Patel S, Cohen F, Dean BJ, De La Torre K, Deshmukh G, Estrada AA, Ghosh AS, Gibbons P, Gustafson A, Huestis MP, Le Pichon CE, Lin H, Liu W, Liu X, Liu Y, Ly CQ, Lyssikatos JP, Ma C, Searce-Levie K, Shin YG, Solanoy H, Stark KL, Wang J, Wang B, Zhao X, Lewcock JW, Siu M. 2015. Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. *J Med Chem* 58:401-18.
106. Heinemann B, Nielsen JM, Hudlebusch HR, Lees MJ, Larsen DV, Boesen T, Labelle M, Gerlach LO, Birk P, Helin K. 2014. Inhibition of demethylases by GSK-J1/J4. *Nature* 514:E1-2.
107. Sawtell NM, Thompson RL. 2016. Herpes simplex virus and the lexicon of latency and reactivation: a call for defining terms and building an integrated collective framework. *F1000Res* 5.
108. Wang L, Brown JL, Cao R, Zhang Y, Kassis JA, Jones RS. 2004. Hierarchical recruitment of polycomb group silencing complexes. *Mol Cell* 14:637-46.
109. Chadwick BP, Willard HF. 2003. Barring gene expression after XIST: maintaining facultative heterochromatin on the inactive X. *Semin Cell Dev Biol* 14:359-67.
110. Du T, Zhou G, Roizman B. 2011. HSV-1 gene expression from reactivated ganglia is disordered and concurrent with suppression of latency-associated transcript and miRNAs. *Proc Natl Acad Sci U S A* 108:18820-4.
111. Tedeschi A, Bradke F. 2013. The DLK signalling pathway--a double-edged sword in neural development and regeneration. *EMBO Rep* 14:605-14.
112. Karney-Grobe S, Russo A, Frey E, Milbrandt J, DiAntonio A. 2018. HSP90 is a chaperone for DLK and is required for axon injury signaling. *Proc Natl Acad Sci U S A* 115:E9899-E9908.
113. Summers DW, Frey E, Walker LJ, Milbrandt J, DiAntonio A. 2020. DLK Activation Synergizes with Mitochondrial Dysfunction to Downregulate Axon Survival Factors and Promote SARM1-Dependent Axon Degeneration. *Mol Neurobiol* 57:1146-1158.

1111 114. Hirai S, Kawaguchi A, Suenaga J, Ono M, Cui DF, Ohno S. 2005. Expression of
1112 MUK/DLK/ZPK, an activator of the JNK pathway, in the nervous systems of the developing
1113 mouse embryo. *Gene Expr Patterns* 5:517-23.

1114 115. Koren S, Walenz BP, Berlin K, Miller JR, Bergman NH, Phillippy AM. 2017. Canu: scalable
1115 and accurate long-read assembly via adaptive k-mer weighting and repeat separation.
1116 *Genome Res* 27:722-736.

1117 116. Vaser R, Sovic I, Nagarajan N, Sikic M. 2017. Fast and accurate de novo genome assembly
1118 from long uncorrected reads. *Genome Res* 27:737-746.

1119 117. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R,
1120 Genome Project Data Processing S. 2009. The Sequence Alignment/Map format and
1121 SAMtools. *Bioinformatics* 25:2078-9.

1122 118. Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities for comparing genomic
1123 features. *Bioinformatics* 26:841-2.

1124 119. Hahne F, Ivanek R. 2016. Visualizing Genomic Data Using Gviz and Bioconductor. *Methods*
1125 *Mol Biol* 1418:335-51.

1126 120. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, Morgan MT, Carey
1127 VJ. 2013. Software for computing and annotating genomic ranges. *PLoS Comput Biol*
1128 9:e1003118.

1129 121. Malin SA, Davis BM, Molliver DC. 2007. Production of dissociated sensory neuron cultures
1130 and considerations for their use in studying neuronal function and plasticity. *Nat Protoc*
1131 2:152-60.

1132 122. Burman LG, Mauro VP. 2012. Analysis of rRNA processing and translation in mammalian
1133 cells using a synthetic 18S rRNA expression system. *Nucleic Acids Res* 40:8085-98.

1134